share_log

ScPharmaceuticals Enrolls First Participant In Pivotal Pharmacokinetic Study Of FUROSCIX Auto-Injector Injection

Moomoo 24/7 ·  Apr 24 08:01

FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor

Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment